Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Total Debt
Short-term and long-term borrowings combined.
Accendra Health, Inc.NYSE: ACH
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 4.4% from a year ago
Total debt stood at $2.17B at the end of Q1 FY2026, down 4.4% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at -7.2% a year.
Context
- Total debt amounted to 89.8% of total assets at the end of Q1 FY2026, up 43.1 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -4.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.23B USD
- Year-over-year change
- +4.4%
- 4-year CAGR
- +18.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.23B | +4.4% |
| FY2024 | 2024-12-31 | 2.14B | -11.0% |
| FY2023 | 2023-12-31 | 2.41B | -13.9% |
| FY2022 | 2022-12-31 | 2.79B | +142.1% |
| FY2021 | 2021-12-31 | 1.15B | — |
Total Debt vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -4.4% is the 6th highest of 11, against a peer median of -4.2%.
- Total debt amounts to 89.8% of total assets for ACH, versus a peer median of 22.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.17B USD | -4.4% | -7.2% | 89.8% | |
| Mar 2026 | CA$278.71M CAD | -20.0% | -38.7% | 24.9% | |
| Mar 2026 | $101.61M USD | +3.5% | -0.6% | 40.7% | |
| Mar 2026 | $81.05M USD | -0.3% | -6.3% | 20.5% | |
| Mar 2026 | $71.97M USD | +131.2% | +20.4% | 48.2% | |
| Mar 2026 | $59.4M USD | +17.8% | +92.8% | 59.6% | |
| Mar 2026 | $41.76M USD | +3.2% | +5.2% | 38.1% | |
| Mar 2026 | $26.45M USD | -8.1% | +74.1% | 17.9% | |
| Apr 2026 | CA$18.21M CAD | -71.3% | +28.9% | 5.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $4.03M USD | -60.9% | +31.1% | 1.0% |
| Mar 2026 | $1.99M USD | -20.1% | +45.7% | 1.0% | |
| Peer median (excluding ACH) | — | -4.2% | +24.7% | 22.7% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55.71M | 69.47M | 243.04M | 49.38M | 281.99M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 681.56M | 763.5M | 598.26M | 690.24M | 95.91M |
| Inventory | 1.5B | 1.33B | 1.11B | 1.13B | 74.44M |
| Other Current Assets | 88.56M | 128.64M | 150.89M | 149.52M | 95.54M |
| Total Current Assets | 2.32B | 2.3B | 2.1B | 2.02B | 547.87M |
| Property, Plant & Equipment (Net) | 511.24M | 858.93M | 840.51M | 864.97M | 365.26M |
| Goodwill | 390.19M | 1.64B | 1.64B | 1.33B | 1.23B |
| Intangible Assets | 243.75M | 483.74M | 361.84M | 296.73M | 136.47M |
| Long-term Investments | 16.32M | 15.46M | 8.45M | 6.11M | 1.34M |
| Tax Assets | 0 | 0 | (8.45M) | 0 | 0 |
| Other Non-current Assets | 53.25M | 96.26M | 149.35M | 134.05M | 172.69M |
| Total Non-current Assets | 1.21B | 3.09B | 2.99B | 2.63B | 1.9B |
| Total Assets | 3.54B | 5.39B | 5.09B | 4.66B | 2.45B |
| Account Payables | 1B | 1.15B | 1.17B | 1.25B | 363.57M |
| Short-term Debt | 43.85M | 15.38M | 204.08M | 40M | 293.27M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 116.4M | 0 | 0 |
| Other Current Liabilities | 182.35M | 227.44M | 191.66M | 425.54M | 220.81M |
| Total Current Liabilities | 1.34B | 1.57B | 1.89B | 1.87B | 947.08M |
| Long-term Debt | 936.23M | 2.47B | 1.88B | 1.8B | 1.87B |
| Deferred Tax Liabilities | 35.31M | 60.83M | 41.65M | 22.46M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 108.94M | 114.94M | 122.59M | 100.13M | 25.15M |
| Total Non-current Liabilities | 1.25B | 2.87B | 2.28B | 2.22B | 1.97B |
| Total Liabilities | 2.6B | 4.44B | 4.17B | 4.09B | 2.91B |
| Common Stock | 150.87M | 152.56M | 153.09M | 154.4M | 152.78M |
| Retained Earnings | 387.62M | 410.01M | 368.71M | 6.02M | (1.08B) |
| Accumulated OCI | (40.59M) | (35.85M) | (31.82M) | (49.34M) | (885K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 938.5M | 945.6M | 924.17M | 565.23M | (460.98M) |
| Total Debt | 1.15B | 2.79B | 2.41B | 2.14B | 2.23B |
| Net Debt | 1.1B | 2.72B | 2.16B | 2.09B | 1.95B |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.